BRISTOL MYERS SQUIBB

Precision medicine tailors CVD treatments to patient subgroups based on unique genetic traits, improving clinical outcomes and quality of life, leveraging insights from hypertrophic cardiomyopathy.

2024 saw significant advancements in skin cancer treatment, including FDA approvals for lifileucel and IBI363, new clinical guidelines for nonmelanoma skin cancer, an updated PDUFA date for subcutaneous nivolumab, and 3-year data for mRNA-4157 combined with pembrolizumab.

The global synthetic biology market was valued at USD 10.7 billion in 2021 and is projected to grow at a CAGR of 21.3% to reach over USD 74.7 billion by 2031, driven by advancements in biotechnology, applications in healthcare, agriculture, and energy, and demand for sustainable solutions. Key players include Bristol-Myers Squibb, Gevo, Inc., Life Technologies, and others. Challenges include regulatory issues, ethical concerns, high R&D costs, and technical challenges, while opportunities lie in sustainable solutions, personalized medicine, and bio-based products.

The inMIND trial results, presented at ASH Annual Meeting, showed Monjuvi plus Rituxan plus Revlimid significantly improved progression-free survival in R/R follicular lymphoma patients compared to placebo. Monjuvi, developed by Incyte, plans to file for FDA approval for R/R FL by 2024, facing competition from other therapies.

ASH meeting featured studies on BTK inhibitors in CLL, including Jaypirca's Phase 3 trial showing improved progression-free survival and fewer side effects. AstraZeneca's Calquence combined with Venclexta reduced progression risk by 35%. Pfizer's Oxbryta withdrawal due to safety concerns raised questions on sickle cell drug approvals. Bristol Myers Squibb presented positive survival data for its GPRC5D-targeted CAR-T therapy, arlo-cel, in multiple myeloma.

DelveInsight's report on PD-1 Non-Small Cell Lung Cancer Market (2020-2034) highlights market growth, approvals, prevalence, therapies, and companies like Merck, Bristol-Myers Squibb, Genentech, and others. Key therapies include KEYTRUDA, OPDIVO, TECENTRIQ, and TIZVENI. Market drivers include premium-priced targeted agents and therapy expansion, while barriers include premium pricing of emerging therapies.

The global oncology-based in-vivo CRO market was valued at USD 1.4 billion in 2024 and is expected to grow at an 8.8% CAGR from 2025 to 2034, driven by demand for immuno-oncology therapies, advancements in in-vivo models, and growing oncology drug approvals from small biotech and pharmaceutical companies. Small firms lead in oncology drug approvals, focusing on innovative treatments like CAR-T cell therapy and monoclonal antibodies. The market is segmented by service, model, end use, and region, with preclinical testing dominating. Key trends include the rise of immunotherapies, outsourcing by biotech firms, AI integration, and strategic alliances between companies and CROs.

Dr. Horan, Dr. Sauder, Dr. Ramsay, and Dr. Yohn are Bristol Myers Squibb employees. Dr. Harvey has affiliations with multiple companies, including Bristol Myers Squibb. Dr. Ramsay holds Bristol Myers Squibb stock. Dr. Keefe consults for various companies and has received royalties. Dr. Davis consults for several companies. Dr. Paul has roles at Karuna Therapeutics, Sage Therapeutics, and Voyager Therapeutics. Dr. Brannan was with Karuna Therapeutics and now consults for Bristol Myers Squibb.

Tasca Therapeutics announced a $52M Series A financing led by Regeneron Ventures and Cure Ventures, with Invus Group participating. Funds will advance CP-383 into Phase 1/2 clinical studies and expand Tasca's drug pipeline. CP-383, a first-in-class molecule, shows promise across multiple cancers. Tasca's platform identifies druggable targets via auto-palmitoylation mapping.

The IDH market is set to grow rapidly due to expanded indications for approved therapies and increased R&D. Key players like Servier and Bayer are developing novel IDH inhibitors, with IDHIFA (enasidenib) being the first-in-class oral targeted inhibitor for IDH2-mutated AML. IDH inhibitors, including TIBSOVO (ivosidenib) and REZLIDA (enasidenib), are FDA and EMA-approved for various cancers. Vorasidenib, in advanced development, aims to treat IDH-mutant diffuse glioma. The market growth is driven by advancements in research and expanding pipeline of IDH inhibitors.